Long term trends of breast cancer incidence according to proliferation status

BMC Cancer. 2022 Dec 21;22(1):1340. doi: 10.1186/s12885-022-10438-1.

Abstract

Background: Long-term breast cancer incidence trends according to proliferation status are poorly described. We studied time-trends in breast cancer incidence, using mitotic count and Ki-67 as markers of proliferation.

Methods: Among 83,298 Norwegian women followed for breast cancer occurrence 1961-2012, 2995 incident breast cancers were diagnosed. Ki-67 was assessed using immunohistochemistry on tissue microarrays and mitoses were counted on whole sections. We compared incidence rates according to proliferation status among women born 1886-1928 and 1929-1977, estimating age-specific incidence rate ratios. We performed multiple imputations to account for unknown proliferation status. Mean values of Ki-67 and mitotic counts were calculated, according to age and birth year. We performed separate incidence analyses for HER2+ and triple negative breast cancers.

Results: Among women aged 40-69 years, incidence rates of tumours with low-proliferative activity were higher among those born in 1929 or later, compared to before 1929, according to Ki-67 and mitotic count. Incidence rates of tumours with high-proliferative activity were also higher in women born in 1929 or later compared to before 1929 according to Ki-67, but not according to mitotic count. Mean values of Ki-67 and mitotic count varied according to age and birth year. In subtype-specific analyses we found an increase of high-proliferative HER2+ tumours according to Ki-67 in women born in 1929 or later, compared to before 1929.

Conclusions: There has been a temporal increase in both low- and high-proliferative breast cancers.

Keywords: Breast cancer; Incidence trends; Ki-67; Mitotic count; Proliferation.

MeSH terms

  • Aged, 80 and over
  • Biomarkers, Tumor
  • Breast Neoplasms* / epidemiology
  • Breast Neoplasms* / pathology
  • Cell Proliferation
  • Female
  • Humans
  • Incidence
  • Ki-67 Antigen
  • Norway / epidemiology
  • Receptor, ErbB-2

Substances

  • Ki-67 Antigen
  • Receptor, ErbB-2
  • Biomarkers, Tumor